Allan Böhm, MD, PhD, MSc (@Allan_Bohm) header
Allan Böhm, MD, PhD, MSc (@Allan_Bohm) profile picture

Allan Böhm, MD, PhD, MSc

@Allan_Bohm

Cardiologist. Founder/CEO @Seerlinq (CE-marked AI heart-failure worsening prediction) & Premedix Clinic. ESC. Democratising precision medicine

seerlinq.com
Joined May 2010
  • Tweets1.8K
  • Following561
  • Followers1.1K
72Media
Photo by Allan Böhm, MD, PhD, MSc (@Allan_Bohm)Photo by Allan Böhm, MD, PhD, MSc (@Allan_Bohm)Photo by Allan Böhm, MD, PhD, MSc (@Allan_Bohm)Photo by Allan Böhm, MD, PhD, MSc (@Allan_Bohm)Photo by Allan Böhm, MD, PhD, MSc (@Allan_Bohm)Photo by Allan Böhm, MD, PhD, MSc (@Allan_Bohm)Photo by Allan Böhm, MD, PhD, MSc (@Allan_Bohm)Photo by Allan Böhm, MD, PhD, MSc (@Allan_Bohm)Photo by Allan Böhm, MD, PhD, MSc (@Allan_Bohm)Photo by Allan Böhm, MD, PhD, MSc (@Allan_Bohm)
Better late than never. Here’s our 2025 Seerlinq wrap-up 🚀 If you told me a year ago we’d achieve all this in 12 months, I’d say: no chance. But 2025 turned out to be a breakthrough year. What we delivered 👇 • CE-marked MDR Class IIb – world’s first non-invasive remote cardiac filling pressure monitoring • Top innovation @ THT Boston • Reimbursed by all Slovak insurers + full reimbursement in Germany • ESC HF Late-Breaker • JACC publication • 4× presentations at ESC Congress Madrid • Strategic partnership with Samsung (HF smartwatch diagnostics) • €4M R&D grant secured • 600+ HF patients monitored • First study: >50% reduction in HF hospitalizations & deaths This is proof that scalable, non-invasive haemodynamic monitoring can move from vision to real-world care - and keep patients out of hospital. Huge thanks to clinicians, patients, partners, insurers, regulators, and our team. 2026 - we’re coming. #HeartFailure #DigitalHealth #MedTech #AIinHealthcare #Cardiology #Seerlinq @rafavidalperez @_antocannata @PragueICU @HanCardiomd @ANazmiCalik
Image from Allan Böhm, MD, PhD, MSc (@Allan_Bohm)
Image from Allan Böhm, MD, PhD, MSc (@Allan_Bohm)
Image from Allan Böhm, MD, PhD, MSc (@Allan_Bohm)
Image from Allan Böhm, MD, PhD, MSc (@Allan_Bohm)
2
10
1,025
Please ignore this paper and do not discontinue statins
NEJM (@NEJM) profile pictureNEJM
@NEJMNov 7
Presented at #ScientificSessions26: In older adults with at least two chronic conditions and no known atherosclerotic cardiovascular disease, statin discontinuation was noninferior to continuation for a composite of myocardial infarction, stroke, or death at 2 years. Full STREAM trial results: nej.md/47U1X9N @AHAScience
A graph from the Original Article "Discontinuing Statins in Older Adults without Cardiovascular Disease." The trial name, STREAM, is in parentheses after the title. The graph shows estimated cumulative incidence of primary-outcome events. The trial results are being presented at the American Heart Association Scientific Sessions 2026. The logo of the New England Journal of Medicine is at the bottom.

ALT A graph from the Original Article "Discontinuing Statins in Older Adults without Cardiovascular Disease." The trial name, STREAM, is in parentheses after the title. The graph shows estimated cumulative incidence of primary-outcome events. The trial results are being presented at the American Heart Association Scientific Sessions 2026. The logo of the New England Journal of Medicine is at the bottom.

17
34
4
308
32,621
Allan Böhm, MD, PhD, MSc retweeted
rafavidalperez (@rafavidalperez) profile picture
rafavidalperez
@rafavidalperezNov 9
Are you ready? #ESCAIsummit26 @escardio is quite near #EHJDigital #ESCDigital Don´t miss @wenzl_florian @NurglKeser6 @BruiningNico @fwasselbergs
1
6
1
9
453
Allan Böhm, MD, PhD, MSc retweeted
NEJM (@NEJM) profile picture
NEJM
@NEJMNov 7
Presented at #ScientificSessions26: Among patients with cardiovascular disease and high lipoprotein(a) levels, pelacarsen lowered the lipoprotein(a) level, but the risk of major cardiovascular events was similar with pelacarsen and placebo. Full phase 3 Lp(a)HORIZON trial results: nej.md/4AcZL9n @AHAScience
A graph from the Original Article " Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a).” The trial name, Lp(a)HORIZON, is in parentheses after the title. The graph shows four-component MACE in full population with lipoprotein(a) level 70 mg/dl. The trial results are being presented at the American Heart Association Scientific Sessions 2026. The logo of the New England Journal of Medicine is at the bottom.

ALT A graph from the Original Article " Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a).” The trial name, Lp(a)HORIZON, is in parentheses after the title. The graph shows four-component MACE in full population with lipoprotein(a) level 70 mg/dl. The trial results are being presented at the American Heart Association Scientific Sessions 2026. The logo of the New England Journal of Medicine is at the bottom.

15
120
31
335
52,548
Opening today the @AHAScience session on AI at the bedside for cardiogenic shock today. Most infarct-related shock develops AFTER arrival. That is the window. STOPSHOCK predicts it at first medical contact: ROC AUC 0.87 Next: prevent it. #stopshock
🤖 Made with AI
Image from Allan Böhm, MD, PhD, MSc (@Allan_Bohm)
5
1
11
696
Five finalists. Four from the US. One from Bratislava. 🇸🇰 @seerlinq is a finalist in the @American_Heart Health Tech Competition 2026, and the only finalist from outside the United States. We pitch this week at #ScientificSessions26 with @AHAScience. The problem: pulmonary capillary wedge pressure is the number that drives heart failure decisions. Until now, getting it meant a catheter or an implanted device. HeartCore estimates it from a finger sensor. • Validated head-to-head against right heart catheterisation, published in @JACCJournals Heart Failure • CE-certified, with substantial reductions in hospitalisations in clinical studies • Already reimbursed in multiple European countries Implants have already proved that pressure-guided HF care works. We want to bring that signal to the millions of patients who will never get one. Health Innovation Pavilion, Chicago: 🗓 Sat 7 Nov: I'll present the science 🗓 Sun 8 Nov: Stefan Karolcik will present the business case Working in HF, remote monitoring or reimbursement? DM me. Congrats to fellow finalists HEARTio, MEGI Health, @MedRhythms and Vascudyne. See you on stage. #HeartFailure
Image from Allan Böhm, MD, PhD, MSc (@Allan_Bohm)
Image from Allan Böhm, MD, PhD, MSc (@Allan_Bohm)
1
3
7
661
Thank you @CraigBeam1 and the judges. @BiykemB, thanks to JACC: Heart Failure for publishing our validation. Would love to hear from @hvanspall @WilfriedMullens @gcfmd @mvaduganathan @ShelleyZieroth on where non-invasive haemodynamics fits in HF care.
2
4
300
Allan Böhm, MD, PhD, MSc retweeted
Prof Chris P Gale (@cpgale3) profile picture
Prof Chris P Gale@cpgale3Aug 30
WOW! Sham #AFib ablation RCT…. neutral
Image from Prof Chris P Gale (@cpgale3)
Image from Prof Chris P Gale (@cpgale3)
9
52
16
211
125,590
Allan Böhm, MD, PhD, MSc retweeted
NEJM (@NEJM) profile picture
NEJM
@NEJMAug 30
Presented at #ESCCongress: In pulmonary hypertension associated with left heart disease and heart failure, pulmonary-artery denervation reduced clinical worsening and recurrent heart failure events as compared with guideline-directed medical therapy alone. Full PADN-HF-PH trial results: nej.md/4wCHY9u @escardio
A graph from the Original Article "Pulmonary Denervation for Heart Failure–Related Pulmonary Hypertension." The trial name, PADN-HF-PH, is in parentheses after the title. The graph shows the time-to-event analysis involving the patients who had clinical worsening, a composite of death, heart or lung transplantation, hospitalization for heart failure, outpatient worsening of heart failure, or a decline in the 6-minute walk distance. The trial results are being presented at the European Society of Cardiology Congress 2026. The logo of the New England Journal of Medicine is at the bottom.

ALT A graph from the Original Article "Pulmonary Denervation for Heart Failure–Related Pulmonary Hypertension." The trial name, PADN-HF-PH, is in parentheses after the title. The graph shows the time-to-event analysis involving the patients who had clinical worsening, a composite of death, heart or lung transplantation, hospitalization for heart failure, outpatient worsening of heart failure, or a decline in the 6-minute walk distance. The trial results are being presented at the European Society of Cardiology Congress 2026. The logo of the New England Journal of Medicine is at the bottom.

3
76
11
207
38,460
What a start to #ESCCongress in Munich! 🇩🇪 Seerlinq’s filling pressures from a fingertip - see it live at Booth DH12. Mon 31 Aug, 08:15: I'm presenting our clinical STOP-DHF trial data Exchange Circle 2, Hall A1. Come say hello! #HeartFailure
Image from Allan Böhm, MD, PhD, MSc (@Allan_Bohm)
Image from Allan Böhm, MD, PhD, MSc (@Allan_Bohm)
1
3
11
424
Primum non nocere… science.org/content/article/…
Exclusive: Death of girl in Chinese gene-editing trial was never made public

Exclusive: Death of girl in Chinese gene-editing trial was never made public

Parents want accountability after study went disastrously wrong, Science and Retraction Watch investigation reveals

science.org
52
Allan Böhm, MD, PhD, MSc retweeted
European Society of Cardiology (@escardio) profile picture
European Society of Cardiology
@escardioJul 29
At #ESCAIsummit26, build confidence in evaluating, developing and implementing AI responsibly, over two days of focused scientific discussion and live demonstration. Explore the Scientific Programme and register: esc365.escardio.org/ESC-Digi… 📍 12–13 November 26 | Basel #ESCDigital
7
4
19
5,320
Allan Böhm, MD, PhD, MSc retweeted
European Society of Cardiology (@escardio) profile picture
European Society of Cardiology
@escardioJul 28
Just days left to benefit from late fee pricing for #ESCCongress 2026. This August, join thousands of cardiovascular professionals for four days of world-leading science, collaboration & exciting opportunities. Register by 31 July to save ow.ly/Agjn50Zsc4Y 📍 28-31 August 2026 | Munich, Germany
1
2
1
12
4,394
Allan Böhm, MD, PhD, MSc retweeted
American College of Cardiology (@ACCinTouch) profile picture
American College of Cardiology
@ACCinTouchJul 23
The updated 2026 ACC Expert Consensus Decision Pathway for the Management of #HFpEF reflects a significant evolution in how HFpEF is understood and treated. Read the full document in #JACC ➡️ bit.ly/3RVs4sl #CardioX
Image from American College of Cardiology (@ACCinTouch)
78
7
147
29,684
Today at Premedix Clinic we randomised our first patient into ZENITH - the global Phase 3 trial of zilebesiran, an #RNAi therapy that controls blood pressure with a single injection every 6 months. Precision medicine, at the frontier! #Hypertension #CardioTwitter
Image from Allan Böhm, MD, PhD, MSc (@Allan_Bohm)
3
8
391
AF and heart failure feed each other. When combined, outcomes get worse - yet new AF often goes undetected until it’s too late. Could @seerlinq remote monitoring catch it silently, with no extra device? Our answer, now in Europace 🧵 academic.oup.com/europace/ar…
Image from Allan Böhm, MD, PhD, MSc (@Allan_Bohm)
2
3
8
925
more replies
At the patient level, it tracked one patient through repeated sinus–AF transitions over months - flagging each episode accurately.
1
24
The point: wearable-grade signals can bring rhythm surveillance to the patients who need it most - at home, continuously, at scale. Accessible, everyday precision medicine. That’s what we’re building. #DigitalHealth #AFib #AI
24
Load more